Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOTRIN MIGRAINE PAIN vs SPRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby alleviating pain and inflammation.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Migraine headache pain relief (OTC),Primary dysmenorrhea,Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Fever reduction
Short-term management of moderate to moderate-severe acute pain (FDA-approved indication)
Ibuprofen 400 mg orally every 4-6 hours as needed, maximum 1200 mg in 24 hours.
Intranasal: 31.5 mg (1 spray) in one nostril, may repeat after 30 minutes; maximum 63 mg (2 sprays) per dose. Subsequent doses every 6-8 hours as needed; maximum 126 mg (4 sprays) per day.
2 hours (1.5-2.5 h in adults; prolonged in elderly and renal impairment).
Terminal elimination half-life is 5-6 hours in adults with normal renal function; may be prolonged to 13-14 hours in elderly patients and 15-20 hours in patients with renal impairment.
Primarily hepatic via CYP2C9; metabolites undergo glucuronidation and renal excretion.
Primarily hepatic via conjugation (glucuronidation) and oxidation (CYP2C9 minor). Metabolites are inactive.
Renal: 90% (metabolites and unchanged, 10-20% unchanged). Biliary/Fecal: <5%.
Renal excretion of unchanged drug and metabolites; after intravenous administration, approximately 92% of the dose is recovered in urine (50% as unchanged ketorolac, 40% as glucuronide conjugates) and 6% in feces.
99% bound to albumin.
99% bound to plasma proteins, primarily albumin (saturable at high concentrations).
0.1-0.2 L/kg. Clinical meaning: Low Vd indicates limited tissue distribution, primarily in plasma.
0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid.
Oral: 80-100% (absolute bioavailability).
Intranasal: approximately 75-80% relative to intravenous administration.
e GFR 30-59 m L/min: No adjustment; e GFR 15-29 m L/min: Reduce dose to 200 mg every 6-8 hours, maximum 600 mg/day; e GFR <15 m L/min: Avoid use.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-60 m L/min), reduce total daily dose by 50% and monitor for renal toxicity.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Use with caution, reduce dose by 50%; Child-Pugh Class C: Avoid use.
Contraindicated in Child-Pugh Class C cirrhosis. For mild to moderate hepatic impairment (Child-Pugh A or B), reduce total daily dose by 50% and monitor for signs of bleeding or hepatic toxicity.
Children weighing ≥50 kg: Same as adult; <50 kg: 7.5-10 mg/kg per dose every 6-8 hours, maximum 30 mg/kg/day.
Not recommended for use in pediatric patients (safety and efficacy not established).
Start at lowest effective dose (200 mg every 6-8 hours), monitor renal function and gastrointestinal bleeding risk; maximum 600 mg/day.
Elderly patients may have increased risk of GI bleeding and renal toxicity. Use lowest effective dose and shortest duration; monitor renal function and adjust dose based on estimated glomerular filtration rate (e GFR).
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning symptoms. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk is increased with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft (CABG) surgery.
Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke; risk of serious GI adverse events; avoid in setting of coronary artery bypass graft (CABG) surgery; renal toxicity; anaphylactoid reactions; severe skin reactions (e.g., Stevens-Johnson syndrome); may blunt the antihypertensive effect of ACE inhibitors; avoid late pregnancy due to risk of premature closure of ductus arteriosus.
Cardiovascular risk: May increase risk of serious cardiovascular thrombotic events.,Gastrointestinal risk: Can cause serious GI adverse events including bleeding, ulceration, and perforation.,Renal toxicity: Monitor renal function; avoid in patients with advanced renal disease.,Hepatic effects: Elevations in liver enzymes; discontinue if signs of hepatic injury occur.,Anaphylactoid reactions: Can occur in patients without prior exposure.,Pregnancy: Avoid in late pregnancy due to risk of premature closure of ductus arteriosus.
Known hypersensitivity to ibuprofen or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; late pregnancy (third trimester).
Hypersensitivity to ketorolac or any NSAID,Active peptic ulcer disease or GI bleeding,Advanced renal impairment (creatinine clearance <30 m L/min),Patients at risk for bleeding or receiving anticoagulants,Labor and delivery (risk of fetal harm),Treatment of perioperative pain in CABG surgery,Concomitant use with other NSAIDs or aspirin,Intrathecal or epidural administration (contains alcohol)
Avoid alcohol and caffeine-containing foods/drinks (coffee, tea, cola, chocolate) due to additive caffeine effects. Grapefruit juice may increase ibuprofen absorption; consider avoidance. No other significant dietary restrictions.
No specific food interactions. Avoid alcohol as it may increase risk of GI bleeding. Take with food or milk to minimize GI upset.
First trimester: Risk of spontaneous abortion and congenital malformations (cardiac, gastroschisis). Second trimester: Avoid due to possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated after 30 weeks gestation due to risk of premature closure of ductus arteriosus and persistent pulmonary hypertension. NSAID use after 20 weeks may cause oligohydramnios from fetal renal dysfunction.
Pregnancy Category C. Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. No adequate studies in first two trimesters; use only if potential benefit justifies risk.
Ibuprofen is excreted into breast milk in low amounts (M/P ratio approximately 0.6-1.0). Peak infant dose is less than 1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; use lowest effective dose for shortest duration.
Excreted in human milk in low amounts. M/P ratio not available. Consider risk of infant NSAID exposure; use with caution, especially in neonates.
No standard pharmacokinetic data mandating dose adjustment in pregnancy. However, increased renal clearance and volume of distribution may require higher doses for efficacy; use lowest effective dose and avoid third trimester. No specific dosage adjustment recommended in product labeling.
No specific dose adjustments recommended for pharmacokinetic changes in pregnancy. Use lowest effective dose for shortest duration.
Motrin Migraine Pain contains ibuprofen 200 mg and caffeine 65 mg per tablet. Caffeine enhances analgesic effect and may help with migraine-associated fatigue. Absorb more rapidly on empty stomach; take at first sign of migraine. Avoid in patients with aspirin allergy, peptic ulcer disease, or uncontrolled hypertension.
SPRIX (ketorolac tromethamine) is an NSAID nasal spray for acute pain. Use lowest effective dose for shortest duration. Avoid in patients with active peptic ulcer, recent GI bleeding, renal impairment (Cr Cl <30 m L/min), or at risk of bleeding. Contraindicated in patients with aspirin or NSAID allergy, and in patients with or at risk of intracranial bleeding. Monitor renal function and GI symptoms. Not for use in pediatric patients. Maximum duration is 5 days.
Take with food or milk if stomach upset occurs.,Do not exceed 2 tablets in 24 hours unless directed by a doctor.,Avoid other caffeine-containing products while taking this medication.,Seek medical attention if migraine is severe or accompanied by stiff neck, speech changes, or vision loss.,Do not use for more than 10 days for headache or 3 days for fever.,Discontinue and contact doctor if rash, swelling, or breathing difficulty occurs.
Use exactly as prescribed; do not exceed 5 days of therapy.,Spray into nostril; do not sniff deeply after spraying.,Avoid alcohol and other NSAIDs while using this medication.,Seek medical help if you experience signs of bleeding, stomach pain, or allergic reaction.,Store at room temperature; do not refrigerate or freeze.,Tell your doctor about all other medications you take, especially blood thinners or other NSAIDs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOTRIN MIGRAINE PAIN vs SPRIX, answered by our medical review team.
MOTRIN MIGRAINE PAIN is a NSAID Analgesic that works by Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby alleviating pain and inflammation.. SPRIX is a NSAID Analgesic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOTRIN MIGRAINE PAIN and SPRIX depend on the specific clinical indication. These are both NSAID Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOTRIN MIGRAINE PAIN is: Ibuprofen 400 mg orally every 4-6 hours as needed, maximum 1200 mg in 24 hours.. The standard adult dose of SPRIX is: Intranasal: 31.5 mg (1 spray) in one nostril, may repeat after 30 minutes; maximum 63 mg (2 sprays) per dose. Subsequent doses every 6-8 hours as needed; maximum 126 mg (4 sprays) per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOTRIN MIGRAINE PAIN and SPRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOTRIN MIGRAINE PAIN is classified as Category C. First trimester: Risk of spontaneous abortion and congenital malformations (cardiac, gastroschisis). Second trimester: Avoid due to possible oligohydramnios and fetal renal impairm. SPRIX is classified as Category C. Pregnancy Category C. Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. No adequate studies in first two trimesters; use only if p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.